{"classes":[{"categories":[{"measurements":[{"comment":"Too few events occurred to calculate the median and upper CI limit","groupId":"OG000","lowerLimit":"71.6","upperLimit":"NA","value":"NA"},{"comment":"Too few events occurred to calculate the upper CI limit","groupId":"OG001","lowerLimit":"72","upperLimit":"NA","value":"77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"Defined as time from date of randomization to date of death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"7 years 3 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}